Login to Your Account

New Antibiotics Welcome

Genentech Hardly 'Resistant': Up to $111M in Deal with RQx

By Randy Osborne
Staff Writer

Tuesday, February 12, 2013
Avalon Ventures scored again for the third time in recent weeks, as antibiotics-focused RQx Pharmaceuticals Inc. is expected to make public today a deal worth as much as $111 million with Genentech, part of Roche AG.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription